| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI:10.3322/caac.21660.
doi: 10.3322/caac.21660
|
| [2] |
Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer[J]. Nature, 2022, 603(7903):942-948. DOI:10.1038/s41586-022-04508-4.
doi: 10.1038/s41586-022-04508-4
|
| [3] |
王永洪, 何弢, 李星, 等. 信迪利单抗致晚期鳞状细胞肺癌患者致死性中毒性表皮坏死松解症1例[J]. 国际肿瘤学杂志, 2022, 49(6):380-382. DOI:10.3760/cma.j.cn371439-20211115-00073.
doi: 10.3760/cma.j.cn371439-20211115-00073
|
| [4] |
Prevel R, Colin G, Calès V, et al. Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1:case report and literature review[J]. Rev Med Interne, 2020, 41(4):284-288. DOI:10.1016/j.revmed.2019.12.023.
doi: S0248-8663(20)30011-4
pmid: 31983550
|
| [5] |
李慧, 杨宇. 免疫检查点抑制剂常见免疫相关不良反应及其管理[J]. 国际肿瘤学杂志, 2021, 48(2):105-108. DOI:10.3760/cma.j.cn371439-20200828-00020.
doi: 10.3760/cma.j.cn371439-20200828-00020
|
| [6] |
Quach HT, Robbins CJ, Balko JM, et al. Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy[J]. Oncologist, 2019, 24(7):872-876. DOI:10.1634/theoncologist.2018-0722.
doi: 10.1634/theoncologist.2018-0722
pmid: 30936376
|
| [7] |
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020, 70(2):86-104. DOI:10.3322/caac.21596.
doi: 10.3322/caac.21596
|
| [8] |
Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45:7-18. DOI:10.1016/j.ctrv.2016.02.003.
doi: 10.1016/j.ctrv.2016.02.003
pmid: 26922661
|
| [9] |
Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis[J]. Circulation, 2020, 141(24):2031-2034. DOI:10.1161/CIRCULATIONAHA.119.044703.
doi: 10.1161/CIRCULATIONAHA.119.044703
pmid: 32539614
|
| [10] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2021[M]. 北京: 人民卫生出版社, 2021:110-112.
|
| [11] |
Stuby J, Herren T, Schwegler Naumburger G, et al. Immune checkpoint inhibitor therapy-associated encephalitis:a case series and review of the literature[J]. Swiss Med Wkly, 2020, 150:w20377. DOI:10.4414/smw.2020.20377.
doi: 10.4414/smw.2020.20377
|
| [12] |
厉发建, 徐娟, 祁永康. 鞘内注射激素联合甲基强的松龙治疗急性格林-巴利综合征28例疗效分析[J]. 医学理论与实践, 2012, 25(5):503-504, 506. DOI:10.3969/j.issn.1001-7585.2012.05.004.
doi: 10.3969/j.issn.1001-7585.2012.05.004
|
| [13] |
王汉萍, 周佳鑫, 郭潇潇, 等. 免疫检查点抑制剂相关毒副作用管理之激素的使用[J]. 中国肺癌杂志, 2019, 22(10):615-620. DOI:10.3779/j.issn.1009-3419.2019.10.02.
doi: 10.3779/j.issn.1009-3419.2019.10.02
|
)
